GetToolImpactFactorPageRequest(projectId=1, fullname=早期乳腺癌新辅助化疗effects addition gemcitabine paclitaxel-first, names=早期乳腺癌新辅助化疗effects addition gemcitabine paclitaxel-first, oldNames=早期乳腺癌新辅助化疗Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial，The Lancet Oncology, Early Online Publication, 19 December 2013, impactFactorMin=null, impactFactorMax=null, sortName=null, sortType=null, tagName=null, tagId=null, bigClassId=null, smallClassId=null, bigclass=null, smallclass=null, source=1, isHighlight=0, categoryId=null, excludeIds=null, categoryIds=null, type=sci)[]0<div class='list-no-data'><div class='no-data-img'><img src='https://img.medsci.cn/web/prod/img/no_data.png' id='noDataImg'/></div><div class='no-data-font' id='noDataFont'>暂无数据</div></div>高级检索共查询到0条结果
高级检索
